Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.

NCT04262024 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Health Education

Interventions

DRUG: cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education
DRUG: cabergoline 1.5-2 mg/week).orally daily for 1 month without health education

Sponsor

Woman's Health University Hospital, Egypt